ABBV vs VRTX · P/E 81, rev $61.16B vs P/E 30, rev $12.00B
AbbVie Inc (ABBV) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the ABBV and VRTX stock pages for the full models.
Not investment advice.